Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
emc, 2025
After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs
Multiple factors are supporting this leadership, including a high prevalence of obesity, advanced healthcare infrastructure, and strong pharmaceutical innovation ecosystems
TrimRxs clinicians can prescribe brand-name medications including Zepbound when appropriate, connecting you to official self-pay pricing that is significantly lower than standard retail pharmacy rates
Eli Lilly, the compound developer, is running the Phase 3 TRIUMPH clinical trial program, and FDA approval is not expected before 2027 at the earliest
Building on this foundation, a 2023 study by Lpez-Hernndez et al
